HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Susanna Gräfe Selected Research

temoporfin

8/2018Photodynamic activity of Temoporfin nanoparticles induces a shift to the M1-like phenotype in M2-polarized macrophages.
1/2017Foscan and foslip based photodynamic therapy in osteosarcoma in vitro and in intratibial mouse models.
10/2016Lipid nanoemulsions and liposomes improve photodynamic treatment efficacy and tolerance in CAL-33 tumor bearing nude mice.
8/2016Inclusion complexation with β-cyclodextrin derivatives alters photodynamic activity and biodistribution of meta-tetra(hydroxyphenyl)chlorin.
8/2015Nanocarriers for photodynamic therapy-rational formulation design and medium-scale manufacture.
3/2015Multifunctional calcium phosphate nanoparticles for combining near-infrared fluorescence imaging and photodynamic therapy.
1/2015Pharmacokinetic and biodistribution study following systemic administration of Fospeg®--a Pegylated liposomal mTHPC formulation in a murine model.
12/2013Multiplexed in vivo fluorescence optical imaging of the therapeutic efficacy of photodynamic therapy.
1/2013Photodynamic therapy with conventional and PEGylated liposomal formulations of mTHPC (temoporfin): comparison of treatment efficacy and distribution characteristics in vivo.
12/2010Efficacy of temoporfin-loaded invasomes in the photodynamic therapy in human epidermoid and colorectal tumour cell lines.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Susanna Gräfe Research Topics

Disease

16Neoplasms (Cancer)
08/2018 - 01/2007
3Phototoxic Dermatitis (Phototoxicity)
01/2018 - 12/2010
2Carcinoma (Carcinomatosis)
12/2013 - 04/2008
1Neoplasm Metastasis (Metastasis)
01/2017
1Osteosarcoma (Osteogenic Sarcoma)
01/2017
1Necrosis
10/2014
1Cicatrix (Scar)
12/2011
1Breast Neoplasms (Breast Cancer)
10/2008
1Colonic Neoplasms (Colon Cancer)
09/2007
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
07/2007
1Pain (Aches)
01/2007

Drug/Important Bio-Agent (IBA)

16temoporfinIBA
08/2018 - 01/2007
8Photosensitizing Agents (Photosensitizers)IBA
01/2017 - 07/2007
81-phenyl-3,3-dimethyltriazene (PDT)IBA
01/2017 - 01/2007
5Pharmaceutical PreparationsIBA
10/2014 - 07/2007
4Liposomes (Liposome)IBA
10/2016 - 05/2007
3LipidsIBA
10/2016 - 05/2007
3chlorinIBA
01/2013 - 07/2007
2Singlet OxygenIBA
10/2016 - 10/2011
2Contrast MediaIBA
03/2015 - 12/2013
1Immune Checkpoint InhibitorsIBA
08/2018
1AcidsIBA
01/2018
1Mannose (D-Mannose)IBA
01/2018
1ChlorineIBA
01/2017
1RNA (Ribonucleic Acid)IBA
10/2016
1Reactive Oxygen Species (Oxygen Radicals)IBA
10/2016
1Peptides (Polypeptides)IBA
03/2015
1Fluorescent Dyes (Fluorescent Probes)IBA
03/2015
1calcium phosphateIBA
03/2015
1Polyethylene (Polythene)IBA
01/2013
1SuspensionsIBA
10/2008
11,1'- (4,4,7,7- tetramethyl- 4,7- diazaundecamethylene)bis- 4- (3- methyl- 2,3- dihydro(benzo- 1,3- thiazole)- 2- methylidene)quinolinium (TOTO)IBA
10/2008

Therapy/Procedure

12Photochemotherapy (Photodynamic Therapy)
01/2017 - 01/2007
2Therapeutics
01/2017 - 12/2013
2Aftercare (After-Treatment)
03/2015 - 01/2007
1Intravenous Injections
08/2016
1Lasers (Laser)
10/2010
1Palliative Care (Palliative Therapy)
04/2008
1Topical Administration
05/2007